57045-35-9

Basic information

• Product Name: (E)-4-(2',4'-dichlorophenyl)-4-oxobut-2-enoic acid
• Synonyms: (E)-4-(2',4'-dichlorophenyl)-4-oxobut-2-enoic acid
• CAS NO: 57045-35-9
• Molecular Weight: 245.062
• Mol File: 57045-35-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (E)-4-(2',4'-dichlorophenyl)-4-oxobut-2-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-4-(2',4'-dichlorophenyl)-4-oxobut-2-enoic acid(57045-35-9)
• EPA Substance Registry System: (E)-4-(2',4'-dichlorophenyl)-4-oxobut-2-enoic acid(57045-35-9)

Safety Data

• Hazardous Substances Data: 57045-35-9(Hazardous Substances Data)

Upstream product

• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 
• 298-12-4 Glyoxilic acid 
• 6000-59-5 glyoxalic acid monohydrate 
• 541-73-1 1,3-Dichlorobenzene 

Downstream Products

• 56428-38-7 3-(2.4-dichlorobenzoyl)-2'.6'-dimethylacrylanilide 
• 1253518-24-9 3-cyano-6-(2,4-dichlorophenyl)-2-methylisonicotinic acid 
• 78874-19-8 2-(2,4-dichlorophenyl)-3-methylquinoxaline 
• 78868-23-2 4-(2,4-Dichloro-phenyl)-2,3-bis-(4-ethyl-phenyl)-4-oxo-butyric acid 
• 78874-40-5 4-(2,4-Dichloro-phenyl)-3-hydroxy-2-morpholin-4-yl-4-oxo-butyric acid 
• 78874-35-8 4-(2,4-Dichloro-phenyl)-3-hydroxy-4-oxo-2-p-tolylamino-butyric acid 
• 78874-33-6 4-(2,4-Dichloro-phenyl)-3-hydroxy-4-oxo-2-phenylamino-butyric acid 
• 78874-23-4 5-(2,4-Dichloro-phenyl)-4-hydroxy-2-phenyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid 
• 78874-42-7 4-(2,4-Dichloro-phenyl)-3-hydroxy-4-oxo-2-piperidin-1-yl-butyric acid 
• 78874-44-9 2-Acetoxy-4-(2,4-dichloro-phenyl)-3-hydroxy-4-oxo-butyric acid 
• 78874-38-1 4-(2,4-Dichloro-phenyl)-2-diethylamino-3-hydroxy-4-oxo-butyric acid 
• 78874-29-0 5-(2,4-Dichloro-phenyl)-2-phenyl-2H-pyrazole-3-carboxylic acid 

Relevant articles and documents

Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents

A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against MTB with MIC ranging from 0.125 to 4 μg/mL. Especially, compound IIIa16 was found to have the best activity with MIC of 0.125 μg/mL against MTB and with MIC in the range of 0.05–0.48 μg/mL against drug-resistant clinical MTB isolates.

Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study

Protein kinase B (PknB) is an essential serine/threonine protein kinase required for Mycobacterium tuberculosis (M. tb) cell division and cell-wall biosynthesis. A high throughput screen using PknB identified a (E)-4-oxo-crotonic acid inhibitor, named YH-8, which was used as a scaffold for SAR investigations. A significant improvement in enzyme affinity was achieved. The results indicated that the α,β-unsaturated ketone scaffold and “trans-” configuration are essential for the activity against PknB. And compounds with an aryl group, especially with electron-withdrawing substituents on benzene ring, exhibited four fold potency than that of YH-8.

CoA adducts of 4-oxo-4-phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis menaquinone biosynthesis pathway

A high-throughput screen led to the discovery of 2-amino-4-oxo-4- phenylbutanoate inhibitors of the 1,4-dihydroxy-2-naphthoyl-CoA synthase (MenB) from the menaquinone biosynthesis pathway in Mycobacterium tuberculosis. However, these compounds are unstabl